NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Karius

Karius

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://kariusdx.com/

Last Round

Series C

May 2, 2024

Est. Valuation

$700M

Total Funding Raised

$350.27M

Company Overview

Karius is a biotechnology company that provides genomic testing for infectious diseases by analyzing microbial DNA from blood samples to assist physicians in making rapid treatment decisions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Precision Medicine, Medical Devices, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

infectious disease diagnosticsliquid biopsypathogen detectionmetagenomic sequencingagnostic pathogen detectionmicrobial cell-free DNAmcfDNAnext-generation sequencingNGS diagnosticsAI diagnosticslaboratory developed testLDTantimicrobial stewardshipbioinformatics platformimmunocompromised patient diagnosticsFDA Breakthrough DeviceCLIA-certified lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Karius Comps

Public and private peers based on sector, stage, and business model.

Karius comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Karius Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 2, 2024
Series BFeb 24, 2020
DebtNov 29, 2018
Series AAug 7, 2017
SeedOct 20, 2014
Seed
Sep 1, 2014

Key People

Founding team and executive leadership

Alec Ford

Chief Executive Officer

Executive Team

Karius Investors

Notable investors and investment history

Karius investors
InvestorRounds
SoftBank Investment AdvisersSeries C, Series B
Waycross VenturesSeries C
Khosla VenturesSeries B, Series A, Series C
S28 CapitalSeed, Series A
Innovation EndeavorsSeries C, Seed, Series A
SoftBank GroupSeries C, Series B
5AM VenturesSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    Karius Focus BAL test identifies 500 pathogens from BAL fluid.

  • Oct 1, 2025

    Karius Spectrum identifies over 1,000 pathogens from a single blood sample.

Karius Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Karius Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Karius's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range209
Year Founded2014
Last FundingMay 2, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.